Mana.bio
Mana.bio is an AI-based drug delivery startup focused on gene therapy, including DNA and RNA-based therapeutics, and vaccines. The company aims to disrupt the drug delivery space using machine learning and nanotechnology, developing innovative lipid nanoparticle formulations for targeted delivery of nucleic acid therapeutics and vaccines. Their platform integrates high-throughput screening with AI/ML to accelerate development and optimize formulations for tissue-specific delivery, safety, and efficacy.
Industries
Nr. of Employees
small (1-50)
Products
Preclinical lipid nanoparticle candidate portfolio (extrahepatic-targeted)
Series of preclinical LNP candidates developed for extrahepatic delivery (examples include lung- and T-cell-targeted formulations) validated in vitro, in mice and in non-human primates for improved potency and reduced immunotoxicity.
Preclinical lipid nanoparticle candidate portfolio (extrahepatic-targeted)
Series of preclinical LNP candidates developed for extrahepatic delivery (examples include lung- and T-cell-targeted formulations) validated in vitro, in mice and in non-human primates for improved potency and reduced immunotoxicity.
Services
Partnership-based access to an AI-driven design and experimental platform to identify and optimize lipid nanoparticle formulations tailored to external nucleic-acid payloads.
Partnership-based access to an AI-driven design and experimental platform to identify and optimize lipid nanoparticle formulations tailored to external nucleic-acid payloads.
Expertise Areas
- AI-driven lipid nanoparticle design
- Non-viral nucleic acid delivery (LNPs)
- High-throughput experimental DBTL workflows
- Preclinical in-vivo validation (rodent and NHP)
Key Technologies
- Machine learning and deep learning (including graph neural networks)
- Design-Build-Test-Learn automation
- High-throughput automated LNP synthesis and encapsulation
- Automated high-throughput screening assays
News & Updates
One of the biggest challenges facing genetic medicines is getting them to the right part of the body. Mana.bio is leveraging AI to design lipid nanoparticles for targeted delivery beyond the liver.
Mana.bio has raised $19.5 million in seed financing to advance its AI platform for lipid nanoparticle discovery and optimization for tissue-specific delivery of nucleic acid therapeutics and vaccines.
Mana.bio has developed new LNP formulations with significant safety and tolerability improvements, including a 100-fold reduction in cytokine elevation and increased tolerable doses, addressing safety concerns in gene therapy.
Mana.bio has partnered with Sheba Medical Center ARC to advance RNA therapies for cancer and autoimmune diseases, leveraging AI-driven LNP technology.
Mana.bio has been accepted into the NVIDIA Inception program to drive AI innovation and enhance RNA delivery technologies.
Mana.bio announced new research at the ASGCT 2025 Annual Meeting, showcasing AI-driven lipid nanoparticle design for targeted RNA delivery to T cells and lungs.
One of the biggest challenges facing genetic medicines is getting them to the right part of the body. Mana.bio is leveraging AI to design lipid nanoparticles for targeted delivery beyond the liver.
Mana.bio has raised $19.5 million in seed financing to advance its AI platform for lipid nanoparticle discovery and optimization for tissue-specific delivery of nucleic acid therapeutics and vaccines.
Mana.bio has developed new LNP formulations with significant safety and tolerability improvements, including a 100-fold reduction in cytokine elevation and increased tolerable doses, addressing safety concerns in gene therapy.
Mana.bio has partnered with Sheba Medical Center ARC to advance RNA therapies for cancer and autoimmune diseases, leveraging AI-driven LNP technology.
Mana.bio has been accepted into the NVIDIA Inception program to drive AI innovation and enhance RNA delivery technologies.
Mana.bio announced new research at the ASGCT 2025 Annual Meeting, showcasing AI-driven lipid nanoparticle design for targeted RNA delivery to T cells and lungs.